Back to Journals » ClinicoEconomics and Outcomes Research » Volume 9

Original Research

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

       
Total article views   HTML views PDF downloads Totals
22,595 Dovepress* 21,171+ 2,021 23,192
PubMed Central* 1,424 464 1,888
Totals 22,595 2,485 25,080
*Since 30 December 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 0 2

View citations on PubMed Central and Google Scholar